COMMUNIQUÉS West-GlobeNewswire

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial
01/02/2024
Accepted for Presentation at the 2024 International Stroke Conference PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company [...]
Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
01/02/2024
WARRINGTON, Pa., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for critical [...]
Sensus Healthcare Announces Retirement of Director Samuel O’Rear
01/02/2024
BOCA RATON, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS ), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for [...]
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
01/02/2024
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain [...]
BioAdaptives Announces Low-Cost AI FYO Smartphone App Tracking System to Detect Unwanted Muscle Mass Loss Reported With Obesity Management
01/02/2024
Free FYO Body Composition Testing for First 100 Subscribers LAS VEGAS, NV, Feb. 01, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire –BioAdaptives, Inc. (OTC: BDPT), a leading manufacturer and distributor of innovative, all- [...]
EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis
01/02/2024
60 Patients Completed Enrollment in Under 9 Months Study Results Expected in the Second Half of 2024 LYON, France, February 1, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, [...]
Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
01/02/2024
NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients [...]
NightHawk’s Scorpius BioManufacturing Subsidiary Announces the Promotion of Joe Payne to President and Chief Operating Officer
01/02/2024
DURHAM, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the [...]
Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
01/02/2024
CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
01/02/2024
SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/ [...]
Soleno Therapeutics to Present at Upcoming February Investor Conferences
01/02/2024
REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]
Ibogaine By David Dardashti Shares Insight On New Study By Stanford University
01/02/2024
MIAMI, Feb. 01, 2024 (GLOBE NEWSWIRE) -- According to researchers at Stanford University, ibogaine may have the potential to restore brain function in individuals who have suffered traumatic brain injuries and witnessed [...]
BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting
01/02/2024
— Blinded data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in poster presentation — — Company to host webcasted conference call to review data on February 5, 2024 at 8:30am EST — MELVILLE, N.Y., [...]
Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
01/02/2024
- On track for PDUFA target action date of May 25, 2024 - CLEVELAND, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced, as part of the review process by the U.S. Food and Drug [...]
Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
01/02/2024
Webcast and Conference Call To be Held Wednesday, February 7th, 2024, 8:30 am ET NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage [...]
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
01/02/2024
TORONTO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of [...]
Quipt Home Medical Corp. to Announce Fiscal First Quarter 2024 Financial Results on February 14, 2024
01/02/2024
CINCINNATI, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “ Company ”) (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, will announce [...]
Dyne Therapeutics to Present at February Investor Conferences
01/02/2024
WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with [...]
Anti-Cancer Drugs Publishes Preclinical Data Demonstrating the Broad Antineoplastic Activity of Panavance’s Misetionamide (GP-2250)
01/02/2024
Misetionamide showed broad antineoplastic activity in 15 different cancer types including multiple human cancer cell lines with no detrimental effect on normal cells Misetionamide reduces energy metabolism by inhibiting [...]

Pages